Dr Reddy’s, Cheminor merger: The right prescription - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • May 22, 2000 - Dr Reddy’s, Cheminor merger: The right prescription

Dr Reddy’s, Cheminor merger: The right prescription

May 22, 2000

It’s finally been announced: Cheminor Drugs (Cheminor) part of the Dr. Reddy’s group is to be amalgamated with Dr. Reddy’s Laboratories (DRL). This comes on the heels of the another merger: that of American Remedies (ARL) with DRL. Cheminor has been the main supplier of bulk drugs to the USA via its US subsidiary Reddy Cheminor Inc. (almost 67% of the turnover of the company, comprised exports to the USA). The company has capacities for Dextromethorpan (a cough suppressant), painkillers such as ibuprofen and naproxen (both used for arthritis), anti–ulcer medicines ranitidine and famotidine and diltiazem (a cardiovascular drug used for controlling blood pressure).

Cheminor has filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline. The company has set a target to file three to five ANDAs every year and have already received approval for ranitidine (75 mg), the anti–ulcerant omeprazole and anti–depressant fluoxetine.

The company has also been proactive on another plane viz. in filing suits challenging the existing product patent of the patent holders. Reddy Cheminor has filed patent suits against multinational giants Astra Zeneca (producer of omeprazole), Bayer (ciprofloxacin) and Eli Lilly (fluoxetine).

Cheminor reported a turnover of Rs 2154 m last year and the merger would lead a turnover of Rs 7084 m for the combined entity. This would also ensure better valuations for the DRL, which has announced plans for a $ 150–200 m ADR issue in the current financial year.

Equitymaster requests your view! Post a comment on "Dr Reddy’s, Cheminor merger: The right prescription". Click here!

  

More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)

Aug 16, 2021

The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

More Views on News

Most Popular

5 Specialty Chemical Stocks that Turned Multibaggers in One Year (Views On News)

Sep 17, 2021

These specialty chemical stocks have surged 200% or more in the last year. Do you own any?

5 Indian Companies that are Leading the AI Race (Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

A Rare Buying Opportunity in an Exciting Stock (Profit Hunter)

Sep 16, 2021

Whether agriculture sector goes through a structural transformation or not, this agrochemical stock has a good chance of winning.

How to Create a Second Income from Trading (Profit Hunter)

Sep 10, 2021

My trading system that works in all kinds of markets.

5 Indian Companies with Over 7% in Dividend Yield (Views On News)

Sep 17, 2021

These stocks will give you better yields than bank deposits.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 22, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - ADCOCK INGRAM COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS